Abstract
Mitochondrial dysfunction, oxidative stress and inflammation have been implicated in the pathogenesis of multiple sclerosis (MS). Therefore, there is a rationale for the use of supplementary coenzyme Q10 (CoQ10) as a potential novel therapeutic agent for this disorder, based on the key roles of this vitamin-like substance in normal mitochondrial function, as an antioxidant and as an anti-inflammatory agent. In this article, the pre-clinical and clinical studies relating to the use of supplementary CoQ10 for the treatment of MS is reviewed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
